Amendment: EMA fees (Regulation 297/97/EC)

This procedure updates the fees charged by the European Agency for the Evaluation of Medicinal Products. It aims to ensure the agency has adequate resources to carry out its essential work in evaluating medicines.

This affects pharmaceutical companies and potentially patients by influencing the cost and speed of drug approvals. The regulation governing the agency's fees is being amended.